Skip to main content
. Author manuscript; available in PMC: 2023 Mar 17.
Published in final edited form as: Cancer Treat Res Commun. 2020 Dec 13;26:100286. doi: 10.1016/j.ctarc.2020.100286

Figure 2 |. Classification of STK11 loss (mutant) patient tumors into positive, NE, and negative subsets.

Figure 2 |

(a) Gene expression of neuroendocrine markers ASCL1 and CALCA in STK11 normal and STK11 loss in TCGA (left) and MLOS (right). (b-c) K-means clustering of STK11 loss patients in TCGA (b) and MLOS (c) into negative, positive, and NE subsets based on the markers NKX2-1, ASCL1, and CALCA. (d) Scatter plot of PC-1(neuroendocrine signature) and PC-2 (differentiation signature) of principal component analysis performed on 544 genes describing variance of STK11-loss subtypes.